Literature DB >> 19794314

Laboratory markers as predictors of mortality in patients with Clostridium difficile infection.

Chaitanya Pant1, Phillip Madonia, Anil Minocha, Kenneth Manas, Paul Jordan, Pat Bass.   

Abstract

Previous studies have identified laboratory markers for severe Clostridium difficile infection (CDI). The most consistent of these markers is the presence of marked leukocytosis. We examined the validity of these markers as predictors of mortality in patients with CDI. We excluded patients with preexisting hematologic conditions that would be expected to impair their ability to demonstrate leukocytosis. On univariate analysis, marked leukocytosis (P = 0.02), thrombocytopenia (P = 0.008), and increased blood urea nitrogen (P < 0.001) and creatinine (P = 0.001) levels were found to be significantly associated with mortality in patients with CDI. However, on logistic regression analysis, only renal impairment was found to be an independent predictor (odds ratio, 5.07). Importantly, in our study, leukocytosis was not an independent predictor after adjustment for other variables, which may be due to our selection criteria when adjusting for confounding variables. We are therefore of the opinion that in immunocompromised hosts who are leukopenic at the time of CDI diagnosis, other laboratory markers should be identified to serve as indicators for severe disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19794314     DOI: 10.2310/JIM.0b013e3181bca525

Source DB:  PubMed          Journal:  J Investig Med        ISSN: 1081-5589            Impact factor:   2.895


  7 in total

1.  Defining acute renal dysfunction as a criterion for the severity of Clostridium difficile infection in patients with community-onset vs hospital-onset infection.

Authors:  D N Shah; N S Bhatt; J K Welch; H L Koo; K W Garey
Journal:  J Hosp Infect       Date:  2013-02-20       Impact factor: 3.926

2.  In vivo animal models confirm an increased virulence potential and pathogenicity of the NAP1/RT027/ST01 genotype within the Clostridium difficile MLST Clade 2.

Authors:  Josué Orozco-Aguilar; Alejandro Alfaro-Alarcón; Luis Acuña-Amador; Esteban Chaves-Olarte; César Rodríguez; Carlos Quesada-Gómez
Journal:  Gut Pathog       Date:  2020-09-22       Impact factor: 4.181

3.  Thrombocytopenia in hospitalized patients with severe clostridium difficile infection.

Authors:  Eric M Fountain; Maggie C Moses; Lawrence P Park; Christopher W Woods; Gowthami M Arepally
Journal:  J Thromb Thrombolysis       Date:  2017-01       Impact factor: 2.300

4.  Ribotype 027 Clostridium difficile infections with measurable stool toxin have increased lactoferrin and are associated with a higher mortality.

Authors:  J H Boone; L R Archbald-Pannone; K N Wickham; R J Carman; R L Guerrant; C T Franck; D M Lyerly
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-01-22       Impact factor: 3.267

5.  Mortality and Clostridium difficile infection: a review.

Authors:  Brett G Mitchell; Anne Gardner
Journal:  Antimicrob Resist Infect Control       Date:  2012-05-30       Impact factor: 4.887

Review 6.  Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review.

Authors:  Claire Nour Abou Chakra; Jacques Pepin; Stephanie Sirard; Louis Valiquette
Journal:  PLoS One       Date:  2014-06-04       Impact factor: 3.240

7.  Mortality Following Clostridioides difficile Infection in Europe: A Retrospective Multicenter Case-Control Study.

Authors:  Jacek Czepiel; Marcela Krutova; Assaf Mizrahi; Nagham Khanafer; David A Enoch; Márta Patyi; Aleksander Deptuła; Antonella Agodi; Xavier Nuvials; Hanna Pituch; Małgorzata Wójcik-Bugajska; Iwona Filipczak-Bryniarska; Bartosz Brzozowski; Marcin Krzanowski; Katarzyna Konturek; Marcin Fedewicz; Mateusz Michalak; Lorra Monpierre; Philippe Vanhems; Theodore Gouliouris; Artur Jurczyszyn; Sarah Goldman-Mazur; Dorota Wultańska; Ed J Kuijper; Jan Skupień; Grażyna Biesiada; Aleksander Garlicki
Journal:  Antibiotics (Basel)       Date:  2021-03-13
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.